[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481038":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":75,"collaborators":20,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":20,"enrollmentInfo":87,"targetDuration":20,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":20,"overallStatus":47,"whyStopped":20,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Imricor Medical Systems","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-Randomized","EXPERIMENTAL","All subjects with ventricular tachycardia associated with ischemic cardiomyopathy will undergo catheter ablation using the Vision-MR Ablation Catheter 2.0",[13],"Device: Vision-MR Ablation Catheter 2.0",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Vision-MR Ablation Catheter 2.0","Catheter ablation of ventricular tachycardia",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Kate Lindborg, Phd","CONTACT","9528188400","kate.lindborg@imricor.com",[28,45,61],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Herzzentrum Leipzig","NOT_YET_RECRUITING","Leipzig","Saxony","04289","Germany","DE",{"type":37,"coordinates":38},"Point",[39,40],12.37129,51.33962,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":20,"phoneExt":20,"email":20},"Sebastian Hilbert",{"facility":46,"status":47,"city":48,"state":20,"zip":20,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Amsterdam UMC","RECRUITING","Amsterdam","Netherlands","NL",{"type":37,"coordinates":52},[53,54],4.88969,52.37403,{"lat":54,"lon":53},[57],{"name":58,"role":24,"phone":59,"phoneExt":20,"email":60},"Michiel Kemme","+31 020-4442244","m.kemme@amsterdamumc.nl",{"facility":62,"status":30,"city":63,"state":20,"zip":64,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"HagaZiekenhuis","The Hague","2545 AA",{"type":37,"coordinates":66},[67,68],4.29861,52.07667,{"lat":68,"lon":67},[71,73],{"name":72,"role":24,"phone":20,"phoneExt":20,"email":20},"Ivo Van Der Bilt, MD, PhD",{"name":74,"role":24,"phone":20,"phoneExt":20,"email":20},"Hemanth Ramanna, MD, PhD",{"type":76,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100481038","vt-ablation-in-the-icmr-100481038",false,"NCT05543798","VT Ablation in the iCMR","Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia","VISABL-VT","Inclusion Criteria:\n\n* Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy)\n* Documented (ECG\u002FEGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure\n* Diagnosis of Ischemic Cardiomyopathy\n* AAD therapy refractory, contraindicated, not tolerated, or not desired\n* 18 years or older\n\nExclusion Criteria:\n\n* Implanted with non-MR compatible medical devices or contraindicated for an MRI\n* Presence of intracardiac thrombus (verified via CT\u002FMRI\u002FTEE\u002FTTE within 48 hours of procedure - or at start of procedure)\n* Thrombocytopenia or coagulopathy\n* Mechanical mitral and\u002For aortic valve precluding access to the left ventricle\n* Severe aortic stenosis\n* Myocardial infarction requiring stent implantation within 90 days of procedure\n* Previous cardiac surgery within 60 days of procedures\n* Known\u002Funcontrolled stroke risks\n* Class IV Heart Failure\n* Ejection Fraction (EF) \\\u003C 25%\n* Patients with a glomerular filtration rate (GFR) \\\u003C 30\n* Women who are pregnant\n* Allergy to contrast agents (e.g., Gadolinium)\n* Active infection\n* Known or suspected myxoma\n* Unstable angina\n* Patients who do not tolerate anticoagulation therapy\n* Previous intertribal septal patch or prosthetic atrial septal defect closure device\n* Life expectancy \\\u003C 12 months\n* Enrollment in another study without sponsor approval","ALL","18 Years",{"count":88,"type":89},64,"ESTIMATED","INTERVENTIONAL",[92],"NA","The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.",[95],"Ventricular Tachycardia","2026-01-06",{"date":98,"type":99},"2026-01-08","ACTUAL",{"date":101,"type":99},"2025-04-10",{"date":103,"type":89},"2027-06",{"name":5,"class":6},3]